Best of the Week
Most Popular
1.US Paving the Way for Massive First Strike on North Korea Nuclear and Missile Infrastructure - Nadeem_Walayat
2.Trump Reset: US War With China, North Korea Nuclear Flashpoint - Video - Nadeem_Walayat
3.Silver Junior Mining Stocks 2017 Q2 Fundamentals - Zeal_LLC
4.Soaring Inflation Plunges UK Economy Into Stagflation, Triggers Government Pay Cap Panic! - Nadeem_Walayat
5.The Bitcoin Blueprint To Your Financial Freedom - Sean Keyes
6.North Korea 'Begging for War', 'Enough is Enough', is a US Nuclear Strike Imminent? - Nadeem_Walayat
7.Bitcoin Hits All-Time High and Smashes Through $5,000 As Gold Shows Continued Strength - Jeff_Berwick
8.2017 is NOT "Just Another Year" for the Stock Market: Here's Why - EWI
9.Gold : The Anatomy of the Bottoming Process - Rambus_Chartology
10.Bitcoin Falls 20% as Mobius and Chinese Regulators Warn - GoldCore
Last 7 days
Stock Market Calm Before The Storm - 20th Oct 17
GOLD Price Creates Bullish Higher Low - 20th Oct 17
Here’s the US’s Biggest Vulnerability in NAFTA Negotiations - 20th Oct 17
The Greatest Investing Lesson Learned from the 1987 Stock Market Crash - 20th Oct 17
Stock Market Time to Go All-in. Short, That Is - 19th Oct 17
How Gold Bullion Protects From Conflict And War - 19th Oct 17
Stock Market Super Cycle Wave C May Have Started - 19th Oct 17
Negative Expectations, Will the Stock Market Correct? - 19th Oct 17
Knowing the Factors Affect your Car Insurance Premium - 19th Oct 17
Getting Your Feet Wet In Crypto Currencies - 19th Oct 17
10 Years Ago Today a Stocks Bear Market Started - 19th Oct 17
1987 Stock Market Crash 30th Anniversary Greatest Investing Lesson Learned - 19th Oct 17
Virgin Media Broadband Down, Catastrophic UK Wide Failure! - 19th Oct 17
The Passive Investing Bubble May Trigger A Massive Exodus from Stocks - 18th Oct 17
Gold Is In A Dangerous Spot - 18th Oct 17
History Says Global Debt Levels Will Lead to Another Crisis - 18th Oct 17
Deflation Basics Series: The Quantity Theory of Money - 18th Oct 17
Attractive European Countries for Foreign Investors - 18th Oct 17
Financial Transcription Services – What investors should know about them - 18th Oct 17
Brexit UK Vulnerable As Gold Bar Exports Distort UK Trade Figures - 18th Oct 17
Surge in UK Race Hate Crimes, Micro-Racism, Sheffield, Millhouses Park, Black on Asian - 18th Oct 17
Comfortably Numb: Surviving the Assault on Silver - 17th Oct 17
Are Amey Street Tree Felling's Devaluing Sheffield House Prices? - 17th Oct 17
12 Real-Life Techniques That Will Make You a Better Trader Now - 17th Oct 17
Warren Buffett Predicting Dow One Million - Being Bold Or Overly Cautious? - 17th Oct 17
Globalization is Poverty - 17th Oct 17
Boomers Are Not Saving Enough for Retirement, Neither Is the Government - 16th Oct 17
Stock Market Trading Dow Theory - 16th Oct 17
Stocks Slightly Higher as They Set New Record Highs - 16th Oct 17
Why is Big Data is so Important for Casino Player Acquisition and Retention - 16th Oct 17
How Investors Can Play The Bitcoin Boom - 16th Oct 17
Who Will Be the Next Fed Chief - And Why It Matters  - 16th Oct 17
Stock Market Only Minor Top Ahead - 16th Oct 17
Precious Metals Sector is on Major Buy Signal - 16th Oct 17
Really Bad Ideas - The Fed Should Have And Defend An Inflation Target - 16th Oct 17
The Bullish Chartology for Gold - 15th Oct 17
Wikileaks Mocking US Government Over Bitcoin Shows Why There Is No Stopping Bitcoin - 15th Oct 17
How to Wipe Out Puerto Rico's Debt Without Hurting Bondholders - 15th Oct 17
Gold And Silver – Think Prices Are Manipulated? Look In The Mirror! - 15th Oct 17
Q4 Pivot View for Stocks and Gold - 14th Oct 17
Gold Mining Stocks Q3’17 Preview - 14th Oct 17
U.S. Mint Gold Coin Sales and VIX Point To Increased Market Volatility and Higher Gold - 14th Oct 17
Yuan and Gold - 14th Oct 17
Tips for Avoiding a Debt Meltdown - 14th Oct 17

Market Oracle FREE Newsletter

3 Videos + 8 Charts = Opportunities You Need to See - Free

The Ebola Outbreak: U.S. Sponsored Bioterror Weapon?

Politics / Conspiracy Theory Aug 24, 2014 - 06:17 PM GMT

By: Global_Research

Politics

We can now be extraordinarily confident that the U.S. government is lying, in key material respects, about the latest Ebola outbreak—and not just because it lies about nearly everything of political consequence. This article shows that there are compelling reasons to believe we are being told three big lies about Ebola. It also offers a simple, rational, yet disturbing, explanation that very tidily accounts for all three lies. The explanation supposes that the current Ebola outbreak consists in an act of U.S.-linked bioterror.


One key U.S. driven lie has to do with the Western MSM’s insistence that nobody of any repute believes that Ebola might be airborne. On this issue, the Public Health Agency of Canada remarks:

In the laboratory, infection through small-particle aerosols has been demonstrated in primates, and airborne spread among humans is strongly suspected, although it has not yet been conclusively demonstrated (1, 6, 13). The importance of this route of transmission is not clear. Poor hygienic conditions can aid the spread of the virus.

A few scientific studies expressing concern about the airborne possibility are cited in this article, and other such studies are not hard to find.

So there are people with authority to speak to the issue who believe that there is some cause for concern regarding the airborne Ebola prospect, but the U.S. government/MSM complex instead lies and acts like this isn’t the case.

Before getting to the second U.S. lie, it is important to mention three facts that have not received enough discussion. First—and this may be of pivotal significance–we still have no ideahow Ebolagot to West Africa. See for yourself; there’s never been an Ebola outbreak in West Africa before.

Perhaps the racist U.S./MSM view is that all African countries are the same, so who cares?

Second, the current outbreak, in terms of the number and international breadth of infections, does seem to be far more contagious than any previous outbreak; as the previous link shows, we now have at least 1,975 cases.

Now pause for a moment and take this fully on board: the 1,975 cases exceed the total number of Ebola cases from 1977 to 2014’s outbreak. So it’s no surprise that we have, for example, signs of infected individuals in Albania.

The second lie really is a lie of nondisclosure, and concerns the reality that the MSM has not told us that we are dealing with a biologically distinct form of Ebola that has never been seen before.

So, consider the following disconcerting information appearing in the New England Journal of Medicine in April 2014 regarding the current West African, Guinean outbreak of Ebola:

Phylogenetic analysis of the full-length sequences established a separate clade for the Guinean EBOV strain in sister relationship with other known EBOV strains. This suggests that the EBOV strain from Guinea has evolved in parallel with the strains from the Democratic Republic of Congo and Gabon from a recent ancestor and has not been introduced from the latter countries into Guinea. Potential reservoirs of EBOV, fruit bats of the species Hypsignathusmonstrosus, Epomopsfranqueti, & Myonycteristorquata, are present in large parts of West Africa.18 It is possible that EBOV has circulated undetected in this region for some time. The emergence of the virus in Guinea highlights the risk of EBOV outbreaks in the whole West African subregion.

Furthermore, from the same study:

The high degree of similarity among the 15 partial L gene sequences, along with the three full-length sequences and the epidemiologic links between the cases, suggest a single introduction of the virus into the human population. This introduction seems to have happened in early December 2013 or even before.

So, the Guinean variant of Ebola we now confront has been found to be sufficiently genetically distinct from all previous versions of Ebola that it has been assigned its own genetic branch, or clade, and it is believed to have evolved in parallel from an ancestor held in common with a variant of Ebola native to the Democratic Republic of Congo and Gabon. Moreover, the current outbreak began not in June or July, but as early as April 2014 and perhaps even earlier than December, 2013.

And, we seem to have a single introduction of the Guinea (West African) Ebola variant into the human population. Thus, we seem not to have, for example, something along the lines of multiple bites of humans by supposedly Guinea variant Ebola infected fruit bats.

Finally, the Western Africa Ebola outbreak does not appear to be traceable to Central Africa or anywhere else, and so we still do not know how Ebola got to West Africa.

Let us briefly summarize before presenting the third U.S. Ebola lie and concluding with a reasonable explanation that ties the three lies together.

The Guinea Ebola variant has never been seen before. It might well be far more contagious than any Ebola variant hitherto encountered; it could even be airborne. We still have no idea how Ebola arose in West Africa, but it did so some time ago—well before the Western MSM started to spew its lies.

Now the third U.S. Ebola lie: In a Matt Drudge-linked article entitled “The Federal Government’s Inconsistent Ebola Story”, we find that the U.S. government is telling two completely inconsistent stories regarding the circumstances surrounding delivery of MappPharmaceuticals’ magic ZMapp Ebola drug to Dr. Kent Brantly and Nancy Writebol. Thus, we have:

According to the CDC, it was Samaritan’s Purse, the private humanitarian organization that employs Dr. Brantley, who reached out to them in an attempt to find an experimental Ebola drug. The CDC says it passed Samaritan’s Purse along to NIH, who referred them to contacts within Mapp.

“This experimental treatment was arranged privately by Samaritan’s Purse,” the CDC said. “Samaritan’s Purse contacted the Centers for Disease Control and Prevention (CDC), who referred them to the National Institutes of Health (NIH). NIH was able to provide the organization with the appropriate contacts at the private company developing this treatment. The NIH was not involved with procuring, transporting, approving, or administering the experimental treatments.”

The New York Times first reported this version of events on Aug. 6, and the statement was posted on the CDC’s website a few days later,where it remains.

But, as the Morning Consult reports in the same article, we also have:

But the NIH told Morning Consult one of its scientists on the ground in West Africa approached the charity before the group had even decided to pursue an experimental alternative.

“The NIH scientist who was in West Africa referred Samaritan’s Purse to company contacts because they were best equipped to answer questions about the status of their experimental treatment,” the agency said in an email to Morning Consult. “This occurred before Samaritan’s Purse decided to pursue an experimental therapy.”

A statement from Samaritan’s Purse also conflicts with the CDC’s telling of events, and indicates the NIH and other government agencies may have played an active role in procuring the drugs.

“The experimental medication given to Dr. Brantley was recommended to us,” the group said. “We didn’t seek it out, but worked with the National Institutes of Health and other government agencies to obtain this medication.”

Hence, we have the U.S. government saying both that delivery of the drug to the aid workers was initially government’s idea, and that it wasn’t initially government’s idea. Since both of these possibilities cannot be true, we have our third U.S. federal Ebola lie.

But whose idea was it, really, to deliver the ZMapp magic serum (which is said to have begun reversing Brantly’s condition within 20 minutes to an hour)? In all likelihood it was the U.S. government’s idea, at a minimum for the following reason mentioned in the Morning Consult article:

If [Mapp] did this on their own, they must have had unbelievable confidence in the product and lawyers who know this up and down,” Vox said. “If they went this alone, their investors should be worried, because that’s reckless. A team of scientists could get in a lot of trouble doing that, and I can’t imagine they run their company that way, especially considering they have support from the Department of Defense.

Let’s put all of the above together and move toward wrapping matters up.We have what appears to be the most contagious variant of Ebola ever encountered, its genetic form is novel in important respects, and we still have no idea how it arose in West Africa.

Yet, we are told that an experimental drug, ZMapp—produced by a previously unheard of U.S. firm with U.S. Department of Defense ties—is functioning in miraculous fashion. Furthermore, the U.S. government cannot keep its story straight about who initiated the delivery of the experimental drug to the U.S. aid workers, but there are compelling reasons to suppose it was the U.S. government that engineered the delivery.

All of the foregoing should prompt us to ask: When was Mapp Pharmaceutical’s magic drug ZMappdeveloped?

The following language, drawn from an article at International Business Times, might provide guidance:

A statement from Mapp said:

“ZMapp is the result of a collaboration between Mapp Biopharmaceutical Inc, LeafBio, DefyrusInc, the US government and Public Health Agency of Canada.

“ZMapp is composed of three ‘humanised’ monoclonal antibodies manufactured in plants, specifically Nicotiana. It is an optimised cocktail combining the best components of MB-003 and ZMAb.

“ZMapp was first identified as a drug candidate in January 2014 and has not yet been evaluated for safety in humans. As such, very little of the drug is currently available. Any decision to use an experimental drug in a patient would be a decision made by the treating physician under the regulatory guidelines of the FDA.

One very interesting thing to note is the parties involved in producing ZMapp. Two of the parties are the U.S. government and the Public Health Agency of Canada—and the Public Health Agency of Canada, you will recall, is the very same agency that “strongly suspects” that Ebola might be airborne (see the second paragraph of this article). Yet, we are constantly told the U.S. government suspects no such thing.

But there are even more important things to consider.

Does “ZMapp was first identified as a drug candidate in January 2014” mean that ZMappwas designed from the ground up, pretty much when the outbreak began, with the specific purpose of treating the Guinea Ebola variant (see above for timing of the outbreak)? Or, does it mean that ZMapp was repurposed in some way to grapple with the Guinea variant? Or does it perhaps mean something else entirely?

In any event, if the above MappPharmaceuticals statement is true, this much is perfectly clear: a major decision about ZMapp and its potential efficacy was made in January 2014, and that decision appears to have been made very close on the heels of the beginning of the current Guinea Ebola outbreak.

Therefore, if ZMapp really is the miraculous success it is purported to be, we are given to believe that, in Research and Development terms, results must have been achieved virtually overnight. This is because with the beginning of the outbreak of the brand newGuinea Ebola variant dated to around December 2013, Mapp could not possibly have had much time before its January 2014 decision to target the Guinea Ebola variant with ZMapp.

Or might Mappin fact have had plenty of time?

One possibility is that Mappdid have plenty of time, because it knew about the brand new Ebola variant before its debut appearance in West Africa. This would be very strong evidence of a bioterror conspiracy, would it not? Of course, we are very far from sure about this prospect.

However, even if we are to believe that Mapp did not know about the novel Guinea Ebola variant before that variant’s first appearance, but did in fact advance anyway with ZMapp againstthe Guinea variant in January 2014, wemust still ask exactly how ZM appended up being effective against a brand new variant Mapp would, under the present assumption, have only just encountered.

Perhaps Mapp had been in the process of designing ZMapp so that it could successfully attack already extant Ebola variants, and whatever properties made it effective against those already extant variants also transferred to the novel Guinea variant?

Maybe.

But if that is so, ZMapp should prove successful against variants of Ebola other than the Guinea variant. Will it?

If it doesn’t prove successful against variants of Ebola other than the Guinea variant, I do not see how one can logically avoid the conclusion that the West African rooted, Guinea variant of Ebola amounts to U.S. government linked bioterror.

Unless, of course, one is willing to invoke what amounts to a miraculous stroke of luck consisting in the design of a solution that successfully attacks something that’s never been seen before and was not anticipated—even though the solution fails against related versions of the same problem.

In closing, please note that the U.S. act of bioterror explanation economically accounts for all three U.S. lies discussed in the article. It explains why the U.S. government is lying about the airborne status of Ebola, why the U.S. government/MSM hybrid is in no hurry to disclose the geographical and virological novelties of the Guinea variant, and, finally, why the U.S. government, out of one side of its mouth, wants to act like its “miracle experimental drug” had to be pried out of its greedy and comprehensive regulatory hands.

It must be stated, though, that there is one last possibility after all, which is that the Dr. Kent Brantly miracle recovery is no real recovery at all.

Dr. Jason Kissner is Associate Professor of Criminology at California State University. Dr. Kissner’s research on gangs and self-control has appeared in academic journals. His current empirical research interests include active shootings. You can reach him atcrimprof2010@hotmail.com

Global Research Articles by Jason Kissner

© Copyright Dr. Jason Kissner, Global Research, 2014

Disclaimer: The views expressed in this article are the sole responsibility of the author and do not necessarily reflect those of the Centre for Research on Globalization. The contents of this article are of sole responsibility of the author(s). The Centre for Research on Globalization will not be responsible or liable for any inaccurate or incorrect statements contained in this article.


© 2005-2017 http://www.MarketOracle.co.uk - The Market Oracle is a FREE Daily Financial Markets Analysis & Forecasting online publication.


Post Comment

Only logged in users are allowed to post comments. Register/ Log in

Catching a Falling Financial Knife